AP
ALNY icon

Atwood & Palmer’s Alnylam Pharmaceuticals ALNY Stock Holding History

Atwood & Palmer’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-150
Closed -$14K – 318
2015
Q4 		$14K Hold
150
– – ﹤0.01% 296
2015
Q3 		$12K Buy
+150
New +$16.7K ﹤0.01% 315

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Atwood & Palmer's ALNY Position: Q1 2016 in Review

Atwood & Palmer sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2016, closing a stake of 150 shares — an estimated $14K sold.

Atwood & Palmer first reported a position in ALNY in Q3 2015 and held it in 2 quarters. The position peaked at $14K in Q4 2015. 255 funds tracked by Wall St. Rank hold ALNY as of Q1 2016.

  • Atwood & Palmer reported no remaining Alnylam Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Atwood & Palmer sold 150 Alnylam Pharmaceuticals shares in Q1 2016, an estimated $14K.
  • Atwood & Palmer first reported a position in Alnylam Pharmaceuticals in Q3 2015 and held it in 2 quarters.
  • Atwood & Palmer's Alnylam Pharmaceuticals position peaked at $14K in Q4 2015.
  • 255 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2016.

Based on Atwood & Palmer's 13F filing for Q1 2016, filed 28 Apr 2016.